BR112012030552A2 - composição imunogênica - Google Patents

composição imunogênica

Info

Publication number
BR112012030552A2
BR112012030552A2 BR112012030552A BR112012030552A BR112012030552A2 BR 112012030552 A2 BR112012030552 A2 BR 112012030552A2 BR 112012030552 A BR112012030552 A BR 112012030552A BR 112012030552 A BR112012030552 A BR 112012030552A BR 112012030552 A2 BR112012030552 A2 BR 112012030552A2
Authority
BR
Brazil
Prior art keywords
immunogenic composition
composition
sublingually
tlr
agonist
Prior art date
Application number
BR112012030552A
Other languages
English (en)
Inventor
Corey Patrick Mallett
Daniel Larocque
Martin Plante
Nadia Ouaked
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BR112012030552A2 publication Critical patent/BR112012030552A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição imunogênica. a presente invenção fornece uma composição imunogênica que compreende um ou mais antígenos e um agonista do receptor tipo toll (tlr) em uma composição oralmente (por exemplo, sublingualmente) administrada.
BR112012030552A 2010-06-03 2011-06-02 composição imunogênica BR112012030552A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1009273.2A GB201009273D0 (en) 2010-06-03 2010-06-03 Novel vaccine
PCT/EP2011/059167 WO2011151431A1 (en) 2010-06-03 2011-06-02 Oral vaccine comprising an antigen and a toll-like receptor agonist

Publications (1)

Publication Number Publication Date
BR112012030552A2 true BR112012030552A2 (pt) 2016-08-16

Family

ID=42471081

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030552A BR112012030552A2 (pt) 2010-06-03 2011-06-02 composição imunogênica

Country Status (15)

Country Link
US (1) US20130089570A1 (pt)
EP (1) EP2575871A1 (pt)
JP (1) JP2013527218A (pt)
KR (1) KR20130082139A (pt)
CN (1) CN102905726A (pt)
AU (1) AU2011260215B2 (pt)
BR (1) BR112012030552A2 (pt)
CA (1) CA2801266A1 (pt)
EA (1) EA201291105A1 (pt)
GB (1) GB201009273D0 (pt)
IL (1) IL223151A0 (pt)
MX (1) MX2012014083A (pt)
SG (1) SG185729A1 (pt)
WO (1) WO2011151431A1 (pt)
ZA (1) ZA201208915B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2804472T3 (es) 2005-12-13 2021-02-08 Harvard College Estructuras para trasplante celular
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
EP2254602B1 (en) 2008-02-13 2018-11-21 President and Fellows of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
US9297005B2 (en) 2009-04-13 2016-03-29 President And Fellows Of Harvard College Harnessing cell dynamics to engineer materials
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
WO2011109834A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
WO2011163669A2 (en) 2010-06-25 2011-12-29 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
US11202759B2 (en) 2010-10-06 2021-12-21 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
CN103347494A (zh) 2010-10-08 2013-10-09 R·P·舍勒科技有限责任公司 使用淀粉的口服疫苗快速溶解剂型
US9603894B2 (en) 2010-11-08 2017-03-28 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
EP2701753B1 (en) 2011-04-27 2018-12-26 President and Fellows of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
EP2701745B1 (en) 2011-04-28 2018-07-11 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
JP6062426B2 (ja) 2011-06-03 2017-01-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ インサイチュー抗原生成癌ワクチン
GB201119999D0 (en) * 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
CA2861107A1 (en) * 2012-01-13 2013-07-18 President And Fellows Of Harvard College Controlled delivery of tlr agonists in structural polymeric devices
US20140086849A1 (en) 2012-09-21 2014-03-27 Elizabeth McKenna Naturally-Occurring CpG Oligonucleotide Compositions and Therapeutic Applications Thereof
EP2804613A4 (en) 2012-01-16 2015-12-09 Elizabeth Mckenna COMPOSITIONS AND METHODS FOR TREATING DISEASES AND HEPATIC DISORDERS
JP5650780B2 (ja) * 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
CA2840959A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition
JP2014169275A (ja) * 2013-02-05 2014-09-18 Nitto Denko Corp 粘膜投与用ワクチン組成物
KR102045029B1 (ko) * 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US10391167B2 (en) 2013-10-03 2019-08-27 Nitto Denko Corporation Mucosal vaccine composition
BR112016006245A2 (pt) * 2013-10-03 2017-08-01 Nitto Denko Corp composição de vacina de mucosa
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
EP2950095B1 (en) * 2014-05-28 2018-08-29 Technische Universität Dresden Cell-based assay and screening methods for modulators of p75NTR signaling
KR101586468B1 (ko) * 2014-12-30 2016-01-18 성균관대학교산학협력단 아주번트 조성물, 이의 제조 방법, 및 이를 포함하는 백신 조성물
KR101577955B1 (ko) * 2014-12-31 2015-12-16 성균관대학교산학협력단 아주번트 조성물, 이의 제조 방법, 및 이를 포함하는 백신 조성물
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
US10286068B2 (en) 2015-04-15 2019-05-14 Ohio State Innovation Foundation Methods to improve induction of IgA antibodies by vaccines
KR101595949B1 (ko) * 2015-05-27 2016-02-19 성균관대학교산학협력단 아주번트 조성물 및 백신 조성물의 제조 방법
CN115531609A (zh) 2016-02-06 2022-12-30 哈佛学院校长同事会 重塑造血巢以重建免疫
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
US10508115B2 (en) * 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
CN108498362A (zh) * 2018-04-17 2018-09-07 睿欧生物科技（上海）有限公司 预防及治疗口腔溃疡的Toll样受体激动剂漱口水
US20200215185A1 (en) * 2019-01-09 2020-07-09 Emv Enhance (Hk) Limited Compositions and methods for enhancing immune response to vaccination and improving vaccine production
CN112778372A (zh) * 2019-11-11 2021-05-11 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用
CN114377122B (zh) * 2022-01-18 2023-04-07 四川大学 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途
WO2024004159A1 (ja) * 2022-06-30 2024-01-04 Ｅｐｓ創薬株式会社 舌下投与用ワクチン組成物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health FACTORS OF AUTOCRINE MOTILITY IN THE DIAGNOSIS AND TREATMENT OF CANCER.
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JPH05339169A (ja) * 1992-03-03 1993-12-21 Dai Ichi Seiyaku Co Ltd 経口ワクチン
WO1993017702A1 (en) * 1992-03-03 1993-09-16 Daiichi Pharmaceutical Co., Ltd. Oral vaccine
CN1120310A (zh) * 1993-03-11 1996-04-10 塞科雷泰克公司 在粘膜表面转运免疫原的聚合粘膜粘合剂
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
EP0729473B1 (en) 1993-11-17 2000-08-23 OM Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9722682D0 (en) 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
US20020197321A1 (en) * 1997-10-27 2002-12-26 Harry Seager Solid dispersing vaccine composition for oral delivery
WO1999064301A1 (fr) 1998-06-08 1999-12-16 Sca Emballage France Emballage a remise a plat rapide
WO2000000462A1 (fr) 1998-06-30 2000-01-06 Om Pharma Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
AU8100101A (en) * 2000-08-04 2002-02-18 Corixa Corp New immunoeffector compounds
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
DE60228229D1 (de) 2001-04-17 2008-09-25 Dainippon Sumitomo Pharma Co Neue adeninderivate
EP1455700A4 (en) 2001-11-16 2007-02-14 3M Innovative Properties Co METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
US7030094B2 (en) * 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
US7288640B2 (en) 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
US7960522B2 (en) * 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
RU2544850C2 (ru) * 2003-01-06 2015-03-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
CA2593746A1 (en) * 2004-12-21 2006-06-29 Vaxinnate Corporation Compositions of influenza viral proteins and methods of use thereof
US20080233105A1 (en) * 2005-09-13 2008-09-25 Green William R Compositions and methods for preventing or treating a viral infection
NZ568211A (en) * 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ568212A (en) * 2005-11-04 2012-03-30 Novartis Vaccines & Diagnostic Changing Th1/Th2 balance in split influenza vaccines with adjuvants
ITMI20061117A1 (it) * 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
CA2601358A1 (en) * 2006-09-08 2008-03-08 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
US20080112974A1 (en) * 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EP2058002A1 (en) * 2007-10-31 2009-05-13 Bestewil Holding B.V. Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine
BRPI0914224A2 (pt) * 2008-06-19 2019-09-24 Variation Biotechnologies Inc composições e métodos para tratar a gripe
EA019138B1 (ru) 2008-06-25 2014-01-30 Инсэрм (Инститют Насиональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Новые иммуноадъювантные соединения на основе флагеллина и их применение
WO2010003009A2 (en) * 2008-07-01 2010-01-07 Emory University Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors
AU2009283557B2 (en) * 2008-08-18 2013-01-17 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Avian influenza virus antigen, and booster immunization method for avian influenza vaccine in combination with mucosal adjuvant which is effective through oral administration
WO2010048520A1 (en) * 2008-10-24 2010-04-29 Glaxosmithkline Biologicals Sa Lipidated imidazoquinoline derivatives
CN101524537B (zh) * 2009-03-26 2012-11-28 成都康华生物制品有限公司 流感口服含片疫苗、流感口服缓释疫苗以及二者制备方法
WO2010111586A2 (en) * 2009-03-27 2010-09-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Mucosal immunization
EP2308506A1 (en) * 2009-10-02 2011-04-13 Mucosis B.V. Adjuvanted intranasal vaccine formulations
WO2011057267A1 (en) * 2009-11-09 2011-05-12 National Jewish Health Vaccine composition

Also Published As

Publication number Publication date
ZA201208915B (en) 2014-04-30
KR20130082139A (ko) 2013-07-18
EP2575871A1 (en) 2013-04-10
GB201009273D0 (en) 2010-07-21
EA201291105A1 (ru) 2013-05-30
AU2011260215A1 (en) 2013-01-17
WO2011151431A1 (en) 2011-12-08
AU2011260215B2 (en) 2014-06-12
CA2801266A1 (en) 2011-12-08
JP2013527218A (ja) 2013-06-27
CN102905726A (zh) 2013-01-30
IL223151A0 (en) 2013-02-03
SG185729A1 (en) 2012-12-28
US20130089570A1 (en) 2013-04-11
MX2012014083A (es) 2013-01-29

Similar Documents

Publication Publication Date Title
BR112012030552A2 (pt) composição imunogênica
BR112013027541A2 (pt) nanotransportadores sintéticos tolerogênicos
BR112016012358A2 (pt) peptídios terapêuticos
CL2008001491A1 (es) Composicion liofilizada que comprende uno o mas antigenos y un agonista del receptor de tipo toll 9 (tlr9); y procedimiento de preparacion.
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
EA201100268A1 (ru) Вакцина
BR112015001414A2 (pt) composição antideriva
BR112013021016A2 (pt) dispositivo portátil para anexar um conector a uma fibra ótica
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
BRPI0907260A2 (pt) "métodos, dispositivos e composições que liberam óxido nítrico"
BR112015027280A8 (pt) nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
DK2152250T3 (da) Faste doseringsformer, der omfatter et enterisk overtræk, med accelereret lægemiddelfrigivelse
PA8850101A1 (es) Combinaciones antitumorales que contienen anticuerpos
CL2014000400A1 (es) Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
BR112012031500A8 (pt) Composições sólidas
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
EP1984405A4 (en) INFLUENZA ANTIGENS, VACCINE COMPOSITIONS AND ASSOCIATED METHODS
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
BR112015021002A2 (pt) forma de dosagem sólida restringente de abuso para liberação imediata com entalhe funcional
ECSP11011072A (es) Antagonistas de los receptores tipo toll 3
UY31622A1 (es) Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2
AR072509A1 (es) Procedimientos, aparatos y productos de programas informaticos para proporcionar informacion
BRPI0719250A2 (pt) Métodos e composições com opalescência reduzida.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]